Polymerase News and Research

RSS

New mechanism of gene regulation involved in tumor progression discovered

Genes contain all the information needed for the functioning of cells, tissues, and organs in our body. Gene expression, meaning when and how are the genes being read and executed, is thoroughly regulated like an assembly line with several things happening one after another.

9 Jan 2019

Study offers new insight on mechanism underlying control of gene expression

Researchers have provided new insight on the mechanism underlying the control of gene expression in all living organisms, according to a study published today in eLife.

8 Jan 2019

New molecular engineering method improves precision of biomarker analysis

Researchers from the University of Helsinki in cooperation with the University of Tartu, Competence Centre on Health Technologies from Estonia, and the Karolinska Institute, published an article in Nature's partner journal Genomic Medicine in which they present Targeted Allele Counting by sequencing along with several of its potential applications.

8 Jan 2019

Horizon Discovery partners with C4XD to validate novel synthetic lethal oncology targets

Horizon Discovery Group today announces that it has entered into an exclusive target discovery partnership with C4XD, a pioneering drug discovery company.

From Revvity 19 Dec 2018

New diagnostic tools may help identify breast cancer patients who could benefit from targeted therapies

A set of emerging diagnostic tools may help identify breast cancer patients who are most likely to benefit from therapies that target important enzymes fueling a range of subtypes, including BCRA-mutated and triple negative cancers.

7 Dec 2018

Scientists discover new inhibitor that decreases lung inflammation

Scientists from the University of Sheffield have discovered a new inhibitor which decreases lung inflammation and could hold the key to treating Acute Respiratory Distress Syndrome - a life-threatening disease which affects thousands of people in the UK.

18 Nov 2018

Speed and error rate of DNA synthesis influenced by DNA structure

The speed and error rate of DNA synthesis is influenced by the three-dimensional structure of the DNA. Using "third-generation" genome-wide DNA sequencing data, a team of researchers from Penn State and the Czech Academy of Sciences showed that sequences with the potential to form unusual DNA conformations, which are frequently associated with cancer and neurological diseases, can in fact slow down or speed up the DNA synthesis process and cause more or fewer sequencing errors.

14 Nov 2018

Antibiotic found in dirt can destroy mutant mycobacteria responsible for TB, study suggests

For decades, doctors have been using antibiotics to fight tuberculosis. And consistently, the microbe responsible for the disease, Mycobacterium tuberculosis, has been fighting back. When confronted with current drugs, such as the antibiotic rifamycin, the bacterium often mutates in ways that make it resistant to the treatment.

1 Nov 2018

Influenza virus can evolve resistance to experimental antiviral drug

The influenza virus can evolve resistance to an anti-flu drug currently in development for use in pandemics but only if there are multiple genetic mutations, a study has found.

25 Oct 2018

New liquid biopsy test confirms remission in patients with HPV-associated oropharyngeal cancer

A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma are free from cancer following radiation therapy.

23 Oct 2018

New diagnostic platform simultaneously screens for all known pathogenic bacteria

Scientists at the Center for Infection and Immunity in the Columbia University Mailman School of Public Health have developed the first diagnostic platform that can simultaneously screen for all known human pathogenic bacteria as well as markers for virulence and antibiotic resistance.

23 Oct 2018

Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients

Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation, results from the phase 3 SOLO-1 trial show.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

New blood test for pediatric brain tumor patients offers safer approach than surgical biopsies

A new blood test for children with brain tumors offers a safer approach than surgical biopsies and may allow doctors to measure the effectiveness of treatment even before changes are identified on scans, according to research led by UCSF Benioff Children’s Hospitals and Children’s National Health System.

16 Oct 2018

Co-Diagnostics awarded patent related to its CoPrimer platform technology

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostic tests, announced today that it has been awarded a patent from the United States Patent and Trademark Office related to the Company's CoPrimer™ platform technology.

10 Oct 2018

New research projects aim to stop spread of African swine fever and prevent outbreak in the U.S.

African swine fever virus threatens to devastate the swine industry and is positioned to spread throughout Asia. The virus has spread throughout the Caucuses region of Eastern Europe and was reported in China in August. It recently was detected in wild boar in Belgium.

10 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

FDA permits marketing of ClonoSEQ assay to detect minimal residual disease in blood cancer patients

Today the U.S. Food and Drug Administration permitted marketing of ClonoSEQ assay, a next generation sequencing-based test for minimal residual disease in patients with acute lymphoblastic leukemiaor multiple myeloma. MRD is a measure of the amount of cancer cells remaining in a person's bone marrow.

30 Sep 2018

Researchers create photoswitchable fluorescent proteins with optical properties

Researchers developed fluorescent proteins that can be controlled by orange and green light. These proteins will help to study processes in living cells. The work was supported by Russian Science Foundation grant, and the results were published in Nature Methods.

28 Sep 2018

TINY cancer detection device shows promise as point-of-care detector of KSHV

Its name is an acronym used to convey its size, but researchers at Cornell Engineering and Weill Cornell Medicine are hoping their hand-held cancer detection device's impact in the developing world is anything but small.

21 Sep 2018